% | $
Quotes you view appear here for quick access.

VPHM Message Board

  • laonda32 laonda32 May 4, 2013 7:03 PM Flag

    New article

    from Propthink; very informative imho:

    Despite Poor Quarter, ViroPharma’s Commercial and Pipeline Progress Continue:

    Although ViroPharma slightly missed Q1 estimates, it appears that the remaining vestiges of the company’s Vancocin franchise, not Cinryze or its European franchises, caused the weakness. Cinryze appears to be taking share, with many of ViroPharma’s new Cinryze patients switching from steroid-based or acute HAE treatment options. The company’s European business is continuing to make progress, and the company’s financial position remains secure. ViroPharma will see multiple sets of clinical data released over the next 12 months, and this should serve to highlight that ViroPharma’s long-term potential is not limited to Cinryze.

    pls google this article!